论文部分内容阅读
目的:了解甘精胰岛素联合二甲双胍治疗对口服降糖药血糖控制不理想的2型糖尿病患者的疗效和安全性。方法:对30例口服降糖药血糖控制不理想的2型糖尿病患者给与甘精胰岛素联合二甲双胍治疗,共12周。治疗前后测身高、体重、空腹血糖(FPG)、餐后2小时血糖(PPG)以及糖化血红蛋白(HbA1c)水平。了解治疗期间低血糖发生情况。结果:治疗后的FPG、PPG以及HbA1c水平明显下降,分别下降了3.03mmol/L、5.10mmol/L和1.98%,差异有统计学意义(P<0.05)。治疗后53.30%的患者HbA1c水平<7.0%。治疗前HbA1c水平≥7.0%-<9.0%的患者,治疗后70.6%的患者HbA1c水平<7.0%,治疗前HbA1c水平≥9.0%的患者,治疗后30.7%的患者HbA1c水平<7.0%,两者的HbA1c达标率有明显差异(P<0.05)。治疗前后体重及BMI无明显差异(P>0.05)。30例患者中仅发生两次轻微低血糖。结论:甘精胰岛素联合二甲双胍治疗对口服降糖药治疗血糖控制不理想的2型糖尿病患者是安全有效的,尤其是对HbA1c水平<9.0%的患者,血糖控制更好,达标率更高。
Objective: To understand the efficacy and safety of glargine and metformin in the treatment of type 2 diabetes patients who are not controlled by oral hypoglycemic agents. Methods: Thirty patients with type 2 diabetes who did not control the blood sugar of oral hypoglycemic agents were treated with glargine and metformin for 12 weeks. Before and after treatment, height, weight, fasting blood glucose (FPG), postprandial blood glucose 2 hours (PPG) and glycosylated hemoglobin (HbA1c) levels. Understand the incidence of hypoglycemia during treatment. Results: After treatment, the levels of FPG, PPG and HbA1c were significantly decreased by 3.03 mmol / L, 5.10 mmol / L and 1.98%, respectively, with significant difference (P <0.05). 53.30% of patients had HbA1c levels <7.0% after treatment. Before treatment, HbA1c level was 7.0% - <9.0% in 70.6% of patients with HbA1c level <7.0%, HbA1c level ≥ 9.0% before treatment, HbA1c level <7.0% in 30.7% of patients after treatment, both HbA1c compliance rates were significantly different (P <0.05). Body weight and BMI had no significant difference before and after treatment (P> 0.05). Only two mild hypoglycemic episodes occurred in 30 patients. CONCLUSIONS: Glargine and metformin are safe and effective for oral hypoglycemic agents in patients with type 2 diabetes who do not control glycemic control. In particular, patients with HbA1c levels <9.0% have better glycemic control and higher compliance rates.